The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2023 | Novel advances in the management of GC/GEJC
Yongqian Shu, MD, PhD, Nanjing Medical University, Nanjing, China, provides an overview of the latest developments in the treatment of gastric or gastroesophageal junction cancer (GC/GEJC). Approvals of avelumab or pembrolizumab with chemotherapy have provided more treatment options for this group of patients and further research in molecular subtypes will provide further strategies. Dr Prof. Shu additionally highlights findings from the RATIONALE-205 (NCT03777657), RATIONALE-306 (NCT03783442), and RATIONALE-311 (NCT03957590), which all assessed tislelizumab in patients with GC/GEJC in various settings. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
